NewSelf vs Competitors 2026: Market Position Among Compounded GLP-1 Providers

NewSelf's Market Position in 2026

the NewSelf program occupies a distinctive position in the 2026 compounded GLP-1 market: price leader with moderate regulatory risk and strict commitment terms. This combination makes it the right choice for price-sensitive patients who do their due diligence — and the wrong choice for patients who prioritize regulatory clean record or commitment flexibility above all else.

Where NewSelf Leads

• Semaglutide price: $99.97–$134.99 vs $189–$299 across competitors
• Tirzepatide price: $144.49 vs ~$249+ for the only comparable offering (GobyMeds)
• All-dosage flat pricing: No upcharge from starter to maximum dose — most competitors charge per dose tier
• Weekly batch testing: Potency, sterility, endotoxicity — documented and disclosed
• Full refund if doctor declines: A stronger protection than most competitors

Where Competitors Win

• Regulatory track record: GobyMeds, Henry Meds, Ro Body, and Hims all lack outstanding FDA warning letters (NewSelf has Feb 2026)
• Commitment flexibility: All major competitors offer month-to-month vs. NewSelf's 3-month minimum
• Tirzepatide breadth: Ro Body offers brand-name Zepbound; Hims offers no tirzepatide; NewSelf's GLP-1 platform and GobyMeds compete directly on compounded
• Platform maturity: Ro and Hims are established full-service health companies; NewSelf's program is exclusively focused on GLP-1

The Bottom Line

NewSelf is the market's lowest-price option for clinician-supervised compounded GLP-1 — and that advantage is meaningful at $44–$200/month less than alternatives. The tradeoffs are real and require due diligence: FDA warning letter, strict cancellation terms, and pricing inconsistency across pages. For patients who manage these factors proactively, NewSelf delivers genuine value in a market historically known for premium pricing.